Navigation Links
Researchers identify a 'life-and-death' molecule on chronic leukemia cells
Date:5/30/2012

  • SMIP-016 is a promising experimental drug that kills chronic leukemia cells.
  • The drug targets a protein called CD37, but it wasn't known how this kills leukemia cells.
  • This study showed unexpectedly that CD37 helps regulate both cell-death and cell-survival signals, explaining how the drug works and how it might be improved.

COLUMBUS, Ohio A new study has identified a life-and-death signaling role for a molecule on the surface of the immune cells involved in the most common form of chronic leukemia. The finding could lead to more effective therapy for chronic lymphocytic leukemia (CLL), an as yet incurable cancer that occurs in more than 16,000 Americans annually.

The study, led by researchers at the Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James), examines how an experimental drug called SMIP-016 kills CLL cells.

Earlier work by the same researchers showed that the drug targets a molecule called CD37, which is found on the surface of CLL cells. In this new study, the researchers discovered that the CD37 molecule has two regions that can concurrently activate two separate pathways in CLL cells, one that leads to cell death and another that promotes cell survival.

The findings show SMIP-016 activates the "death" part of the molecule, and they suggest that blocking the "survival" part of the molecule could improve the drug's effectiveness, the researchers say.

The study is published in the May issue of journal Cancer Cell.

"These findings open new possibilities for the use of immune-based therapy for treating CLL," says principal investigator Dr. John Byrd, a CLL specialist and professor of Medicine, of Medicinal Chemistry and of Veterinary Biosciences.

"We are already targeting the cell-death pathway using SMIP-016, and we might be able to optimize the drug's effectiveness by simultaneously blocking the cell-survival region of the molecule with a second antibody," he says.

Byrd notes that drugs that can block the cell-survival pathway already exist.

"We were very surprised and excited to find that CD37 is directly involved in regulating survival and cell-death pathways," says first author Rosa Lapalombella, a research scientist in Byrd's laboratory. "That's not usually the case for molecules of this kind."

Co-principal investigator Dr. Natarajan Muthusamy, associate professor of Medicine, notes that CD37 belongs to a family of molecules called tetraspanins, which usually only facilitate signaling by bringing together other molecules that when combined issue signals.

"This work is a great example of collaborative research involving several laboratories," says researcher and co-principal investigator Dr. Michael Freitas, associate professor of molecular virology, immunology and medical genetics, whose laboratory contributed to the global proteomic work of how CD37 signals. "The support for, and emphasis on, team science is a major driving strength of Ohio State and contributed to this project's findings," he says.

Byrd hopes to begin a clinical trial soon that tests SMIP-016 combined with a drug that blocks the survival pathway.

"Overall, these findings reinforce our belief SMIP-016 could be an effective agent for treating CLL and other malignancies that sometimes express the CD37 protein, including non-Hodgkin's lymphoma and acute lymphoblastic leukemia," says Byrd, who is the D. Warren Brown Chair of Leukemia Research.


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. GW researchers discover biomarker for advanced bile duct fibrosis and bile duct cancer
2. Researchers restore neuron function to brains damaged by Huntingtons disease
3. UC San Diego researchers receive new CIRM funding
4. Ben-Gurion U. researchers successfully test solar desalination system for arid land agriculture
5. McMaster University researchers discover drug destroys human cancer stem cells but not healthy ones
6. Barrow researchers use magic for discoveries
7. Researchers present new findings for novel pancreatic cancer vaccine
8. Dartmouth researchers investigate the cognitive effects of athlete head impacts
9. Fish Pedicure a Recipe for Bacterial Infection, Researchers Warn
10. Fox Chase researchers find no disparities in imaging before breast cancer surgery
11. Researchers undertake radical new cancer survivorship study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Kenosha, Wisconsin (PRWEB) , ... December 07, 2016 , ... ... the extraordinary new MedMaster™ MPCNGX . The MPCNGX is a multi-function, sealed, LED ... the right amount of light where and when it’s needed. , A ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... to treat wrinkles and deep lines by smoothing and tightening the skin of ... techniques out there to address facial aging with very little downtime, Silhouette Instalift ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... a women growing up with a schizophrenic mother in a unique, personal perspective ... who specializes in treating trauma and addictive disorders at her private psychotherapy practice. ...
(Date:12/7/2016)... ... December 07, 2016 , ... In the early morning ... to an emergency medical call when he lost control of his patrol car. The ... from his vehicle, he was transported to Atlanta Medical Center, where he later succumbed ...
(Date:12/7/2016)... , ... December 07, 2016 , ... Castle Dermatology Institute ... several ways to restore a more youthful appearance to the face. Dr. Peyman Ghasri ... along with a variety of other treatments, to rejuvenate and renew the facial appearance. ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... Biosimilar Clinical Trial & Opportunity Insight" report by PNS Pharma gives comprehensive ... Currently 5 biosimilar version of Lantus are commercially available in ... , Czech Republic , Estonia , ... Slovakia , United Kingdom for the treatment ... in 2014. Lantus is the brand name for Insulin Glargine, a ...
(Date:12/7/2016)... Global Cervical Dysplasia Market: Scope and ... dysplasia market analyzes the current and future prospects ... executive summary, including a market snapshot that provides ... The research is a combination of primary and ... our research efforts along with information collected from ...
(Date:12/7/2016)... -- A new investigational drug originally developed for type 2 ... of the world,s first treatment to impede the progression of ... in the journal Science Translational Medicine . ... for millions of people living with Parkinson,s disease," says ... Research Institute,s Center for Neurodegenerative Science , chairman ...
Breaking Medicine Technology: